German S. P.
- Country
- Spain
- Department
- Digestive Pathology
Research Overview
- HepaStem Long-Term Safety Registry – Registry for Patients who have been administered HepaStem
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
Data & Insights
Has run more than one trial at 128 of 204 partner sites.
Specializations
Liver Disease Management
This investigator specializes in treating various forms of liver conditions, with particular emphasis on non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). Their research encompasses therapeutic approaches for patients with different stages of liver fibrosis and cirrhosis.
- Steatohepatitis Treatment
- Fibrosis Management
- Cirrhosis Care
Hepatic Disorders
The investigator focuses on advanced treatments for various hepatic conditions, including hepatic encephalopathy and drug-induced liver injury. Their work extends to innovative therapeutic approaches such as fecal microbiome transplantation for liver disease management.
- Hepatic Encephalopathy Treatment
- Hepatotoxicity Management
- Microbiome-Based Therapies
Novel Therapeutics
Their research encompasses emerging therapeutic modalities, including cell-based treatments and investigation of novel compounds. The investigator studies interventions for various liver conditions, including allergic conditions affecting liver function.
- Cell Therapy Applications
- Pharmacokinetic Studies
- Inflammatory Disease Treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.